Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer. (REMNANT)
Primary Purpose
Non Small Cell Lung Cancer
Status
Suspended
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Afatinib
Immediate surgery
Sponsored by

About this trial
This is an interventional treatment trial for Non Small Cell Lung Cancer focused on measuring NSCLC, Early stage, Phase II, Randomized, EGFR mutated
Eligibility Criteria
Inclusion Criteria:
Histological or cytological diagnosis of NSCLC;
- Patients considered operable and with resectable tumor with curative intent (anatomical resection and systematic lymph node dissection) based on evaluation by a thoracic multi-disciplinary team composed of at least a thoracic surgeon, oncologist and radiologist;
- Stage I-III (T1a-3, N0-1, M0 according to UICC version 7) NSCLC by local staging criteria potentially treatable by radical (curative) surgery. Patients with T1 tumor at baseline will be limited to 20%;
- Radiologically measurable disease according to RECIST criteria 1.1; assessed by chest and upper abdomen CT scan within 2 weeks (+1 week) prior to registration); brain CT scan or MRI according to local practice;
- No prior treatment for NSCLC is allowed;
- Adequate tissue in terms of quality and quantity for EGFR local testing.
Exclusion Criteria:
- no adequate bone marrow function within 2 weeks prior to randomization
- no adequate liver function. Patients with Gilbert's syndrome total bilirubin must be below 4 times institutional upper limit of normal; within 2 weeks prior to randomization
- no adequate renal function within 2 weeks prior to randomization
- known positivity to human immunodeficiency virus (HIV), hepatitis B or hepatitis C;
- known history of allergic reactions attributed to compounds of similar chemical or biological composition;
- history of a hematologic or primary solid tumor malignancy, unless no evidence of that disease for 5 years, except pT1-2 prostatic cancer Gleason score < 6, superficial bladder cancer, non melanoma skin cancer or carcinoma in situ of the cervix;
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Neo adjuvant afatinib
Immediate surgery
Arm Description
once daily afatinib at a dose of 40 mg for 8 weeks followed by surgery with curative intent (anatomical resection and systematic lymph node dissection).
immediate surgery with curative intent (anatomical resection and systematic lymph node dissection).
Outcomes
Primary Outcome Measures
Decrease in cT-stage
decrease in cT-stage descriptor measured according to RECIST 1.1
Secondary Outcome Measures
Response Rate
proportion of patients whose response is either complete response (CR) or partial response (PR) using RECIST 1.1;
Change in surgical treatment intent and technique
Full Information
NCT ID
NCT02470065
First Posted
June 10, 2015
Last Updated
January 21, 2016
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
1. Study Identification
Unique Protocol Identification Number
NCT02470065
Brief Title
Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.
Acronym
REMNANT
Official Title
Resectable EGFR Mutant NSCLC With (or Without) Afatinib as Neoadjuvant Treatment; REMNANT an Exploratory Study of the EORTC Lung Cancer Group
Study Type
Interventional
2. Study Status
Record Verification Date
January 2016
Overall Recruitment Status
Suspended
Why Stopped
Study never started
Study Start Date
January 2016 (undefined)
Primary Completion Date
September 2018 (Anticipated)
Study Completion Date
January 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a multicenter, randomized, 1:1, non-comparative phase II trial. Patients with early stage NSCLC will be randomized between ARM A: neoadjuvant afatinib followed by surgery and ARM B: immediate surgery with curative intent.
Detailed Description
This is a multicenter, prospective, open-label, randomized, non-comparative, two-arm phase II trial aiming to evaluate afatinib treatment in pre-operative setting in patients with EGFR mutated NSCLC.
After signing of the informed consent, patients will be registered and screened for eligibility and upon confirmation of all eligibility criteria, patients will be randomized 1:1 to:
Arm A: once daily afatinib at a dose of 40 mg for 8 weeks followed by surgery with curative intent (anatomical resection and systematic lymph node dissection).
Arm B: immediate surgery with curative intent (anatomical resection and systematic lymph node dissection).
Response evaluation in the pre-operative arm will be performed through CT scans at baseline, 4 and 8 weeks.
The first 5 patients enrolled in arm A will be part of a safety run-in to check that afatinib treatment doesn't delay surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non Small Cell Lung Cancer
Keywords
NSCLC, Early stage, Phase II, Randomized, EGFR mutated
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
38 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Neo adjuvant afatinib
Arm Type
Experimental
Arm Description
once daily afatinib at a dose of 40 mg for 8 weeks followed by surgery with curative intent (anatomical resection and systematic lymph node dissection).
Arm Title
Immediate surgery
Arm Type
Active Comparator
Arm Description
immediate surgery with curative intent (anatomical resection and systematic lymph node dissection).
Intervention Type
Drug
Intervention Name(s)
Afatinib
Intervention Description
once daily afatinib at a dose of 40 mg for 8 weeks
Intervention Type
Procedure
Intervention Name(s)
Immediate surgery
Intervention Description
anatomical resection and systematic lymph node dissection
Primary Outcome Measure Information:
Title
Decrease in cT-stage
Description
decrease in cT-stage descriptor measured according to RECIST 1.1
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Response Rate
Description
proportion of patients whose response is either complete response (CR) or partial response (PR) using RECIST 1.1;
Time Frame
8 weeks
Title
Change in surgical treatment intent and technique
Time Frame
8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histological or cytological diagnosis of NSCLC;
Patients considered operable and with resectable tumor with curative intent (anatomical resection and systematic lymph node dissection) based on evaluation by a thoracic multi-disciplinary team composed of at least a thoracic surgeon, oncologist and radiologist;
Stage I-III (T1a-3, N0-1, M0 according to UICC version 7) NSCLC by local staging criteria potentially treatable by radical (curative) surgery. Patients with T1 tumor at baseline will be limited to 20%;
Radiologically measurable disease according to RECIST criteria 1.1; assessed by chest and upper abdomen CT scan within 2 weeks (+1 week) prior to registration); brain CT scan or MRI according to local practice;
No prior treatment for NSCLC is allowed;
Adequate tissue in terms of quality and quantity for EGFR local testing.
Exclusion Criteria:
no adequate bone marrow function within 2 weeks prior to randomization
no adequate liver function. Patients with Gilbert's syndrome total bilirubin must be below 4 times institutional upper limit of normal; within 2 weeks prior to randomization
no adequate renal function within 2 weeks prior to randomization
known positivity to human immunodeficiency virus (HIV), hepatitis B or hepatitis C;
known history of allergic reactions attributed to compounds of similar chemical or biological composition;
history of a hematologic or primary solid tumor malignancy, unless no evidence of that disease for 5 years, except pT1-2 prostatic cancer Gleason score < 6, superficial bladder cancer, non melanoma skin cancer or carcinoma in situ of the cervix;
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sanjay Popat, PhD
Organizational Affiliation
Royal Marsden NHS Foundation Trust
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.
We'll reach out to this number within 24 hrs